Teva names new R&D head and CMO

Israeli generics giant Teva Pharmaceutical Industries (NYSE: TEVA) announced today the appointment of Eric Hughes as executive vice president, global R&D and chief medical officer. Dr Hughes will begin his employment on August 1, 2022, and will be based out of Teva's US headquarters in Parsippany, New Jersey.

Dr Hughes joins Teva with nearly 20 years of experience in all phases of drug development in leading global pharmaceutical companies, most recently as senior VP of clinical development and translational medicine at Vertex Pharmaceuticals (Nasdaq: VRTX), and prior to that as head of the immunology, Hepatology & Dermatology Global Development Unit at Novartis (NOVN: VX).

"Eric brings nearly 20 years of leadership roles with a proven track record in a variety of R&D functions for global pharmaceutical companies, and has a successful record of accomplishment fostering productive collaborations with key opinion leaders and patient advocacy groups,” said Kåre Schultz, Teva's president and chief executive. "As an accomplished scientist with specialty training in infectious diseases and immunology, combined with his track record of leading clinical development activities and talent across multiple therapeutic areas around the globe, I believe Eric has the experience and expertise to lead our Global R&D function and execute on the company-wide vision for innovation and growth going forward," he added.